Healthcare >> Analyst Interviews >> March 22, 2019
Major Pharmas Becoming Increasingly Comfortable with Gene Therapy
Yun Zhong is an Equity Research Analyst and Director of biotechnology research at Janney Montgomery Scott LLC. Dr. Zhong joined Janney in 2017 with over seven years of experience as an associate covering the biotechnology industry. He has experience in several therapeutic areas, including gene therapy, rare diseases, central nervous system disorders, infectious diseases, hepatobiliary disorders, among others. Earlier, Dr. Zhong spent three years at SunTrust Robinson Humphrey. Between 2011 and 2014, he worked as a biotechnology equity research associate at Cowen and Company. Dr. Zhong received his Ph.D. in neuroscience and molecular biology from Rockefeller University, and M.S. and B.S. degrees in biophysical engineering from Osaka University in Japan. He also was a postdoctoral fellow in neurology at New York’s Mount Sinai School of Medicine. Profile
Word count: 3,466
TWST: What is your coverage universe, and for it overall, how do you see the rest of 2019 playing out?